Fosrenol approved in predialysis patients

Patients with chronic kidney disease and hyperphosphataemia can now be treated with Fosrenol (lanthanum carbonate) even if they have not yet started dialysis.

Alongside Alu-Cap (aluminium hydroxide) and Phosex (calcium acetate), Fosrenol is the third phosphate binder to be licensed for predialysis use.

The drug, which comes as chewable tablets, can be used in this setting when a low-phosphate diet fails to reduce serum phosphate levels below 1.78mmol/l. As lanthanum is mainly excreted in bile, monitoring of liver function is recommended.

View Fosrenol drug record

Further information: Shire

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Skin cancer warning for actinic keratosis treatment

Skin cancer warning for actinic keratosis treatment

Patients treated with ingenol mebutate (Picato) should...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

Drug shortages - live tracker

Drug shortages - live tracker

Added: Accupro, Dermovate, Norinyl-1.
Use our...

Anti-Anginal Preparations, Summary by Pharmacological Class

Anti-Anginal Preparations, Summary by Pharmacological Class

Available formulations of anti-anginal drugs.